SCO-940/CT-G32
Sources
company_release, as of 2026-11-04
https://www.scohia.com/eng/sys/news/261104_sco940_tideseurope_en/
SCOHIA PHARMA, Inc. announced today that the first preclinical study results for its next-generation obesity drug candidate SCO-940/CT-G32 were presented at TIDES Europe. Development is on track for an IND submission to the U.S. FDA in February next year and first patient dosing in the second quarter by our strategic partner, Celltrion Inc.
SCOHIA PHARMA news dated 2026.11.04
Studies
No trial is in this file.